# A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

> **NCT01943838** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 18 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** SAR245408

## Key facts

- **NCT ID:** NCT01943838
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01943838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01943838, "A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01943838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*